Sofwave Receives FDA Clearance for Treating Upper Arm Skin Laxity
The FDA clearance of Sofwave to treat upper arm skin laxity comes as the American Society of Plastic Surgeons reports brachioplasty procedures grew 25% between 2019-2022.
The FDA clearance of Sofwave to treat upper arm skin laxity comes as the American Society of Plastic Surgeons reports brachioplasty procedures grew 25% between 2019-2022.
The injectable treatment showed a 30-percentage-point advantage over placebo in submental fat responder rates after a single treatment cycle, supporting plans for a regulatory filing in China by year-end.